{"protocolSection":{"identificationModule":{"nctId":"NCT05128422","orgStudyIdInfo":{"id":"OPENS-1A"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Normobaric Hyperoxia Combined With Endovascular Treatment for Acute Ischemic Stroke","officialTitle":"Normobaric Hyperoxia Combined With Endovascular Treatment for Acute Ischemic Stroke Patients Within 6-24 Hours of Symptom Onset"},"statusModule":{"statusVerifiedDate":"2022-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-10-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-10-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-10-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-10-28","studyFirstSubmitQcDate":"2021-11-09","studyFirstPostDateStruct":{"date":"2021-11-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-03","lastUpdatePostDateStruct":{"date":"2023-07-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficiency of normobaric hyperoxia combined with endovascular treatment for acute ischemic stroke patients with stroke onset 6-24 hours."},"conditionsModule":{"conditions":["Stroke","Endovascular Treatment","Neuroprotection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NBO+EVT group","type":"EXPERIMENTAL","description":"Normobaric hyperoxia Combined with Endovascular therapy group were given 100% oxygen via a face mask initiated before vascular recanalization (10L/min for 4h) . In addition, the patient will be given endovascular therapy surgery.","interventionNames":["Other: Normobaric oxygen therapy"]},{"label":"EVT group","type":"NO_INTERVENTION","description":"The Endovascular therapy group were given room air. And the patient will also be given endovascular therapy surgery."}],"interventions":[{"type":"OTHER","name":"Normobaric oxygen therapy","description":"it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group","armGroupLabels":["NBO+EVT group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Early neurologic improvement (ENI) at 24 hours","description":"ENI was defined as percent change NIHSS≥30%; Percent change NIHSS was defined as \\[(admission NIHSS score-24-hour NIHSS score)x100/admission NIHSS score\\];","timeFrame":"24 ± 12 hours"}],"secondaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale(NIHSS) Score","description":"the NIHSS is a stroke severity score that is composed of 11 items; range from 0 to 42, higher values indicate more severe deficits","timeFrame":"4 hours ± 15 minutes, 24 ± 12 hours; 7 ± 2 days after randomization"},{"measure":"modified Rankin Scale score (mRS)","description":"secondary clinical efficacy endpoint;the mRs is an ordinal disability score of 7 categories (0 = no symptoms to 5 = severe disability, and 6 = death)","timeFrame":"90 ± 14 days after randomization"},{"measure":"Change in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 24 hours","description":"secondary clinical efficacy endpoint;the NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severe deficits)","timeFrame":"24 ± 12 hours after randomization"},{"measure":"Barthel Index (BI)","description":"secondary clinical efficacy endpoint;the BI is an ordinal disability score of 10 categories(range from 0 to 100, higher values indicate better prognosis);","timeFrame":"90 ± 14 days after randomization"},{"measure":"Revascularization on 24-hour follow-up imaging","description":"secondary imaging efficacy endpoint;Successful recanalization was defined as mTICI 2b or 3","timeFrame":"24 ± 12 hours hours after randomization"},{"measure":"Early neurologic deterioration","description":"NIHSS score increased by more than 4 points);the NIHSS is a stroke severity score composed of 11 items (range from 0 to 42, higher values indicate more severe deficits);clinical safety endpoint;","timeFrame":"24 ± 12 hours after randomization"},{"measure":"Symptomatic Intracerebral Hemorrhage","description":"imaging safety endpoints;Deterioration in NIHSS score of ≥4 points within 24 hours;per ECASS III definition and per Heidelberg bleeding classification","timeFrame":"24± 12 hours hours after randomization"},{"measure":"Mortality","description":"clinical safety endpoint;","timeFrame":"90 ± 14 days after randomization"},{"measure":"Stroke recurrence","description":"clinical safety endpoint;","timeFrame":"90 ± 14 days，180 ± 30 days after randomization"},{"measure":"The 5-level EuroQol five dimensions questionnaire（EQ-5D-5L）score","description":"secondary clinical efficacy endpoint, Quality of Life score; The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.","timeFrame":"90 ± 14 days after randomization"},{"measure":"Delta NIHSS","description":"Delta NIHSS was defined (admission NIHSS score-24-hour NIHSS score).","timeFrame":"24 ± 12 hours after randomization"},{"measure":"Percent change NIHSS","description":"Percent change NIHSS was defined as \\[(admission NIHSS score-24-hour NIHSS score)x100/admission NIHSS score\\]","timeFrame":"24 ± 12 hours after randomization"},{"measure":"Cerebral infarct volume","description":"Infarct volume is evaluated mainly through brain MRI(DWI) or CT","timeFrame":"36 ± 12 hours after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age≥18;\n* Suspected lage vessel occlusion of acute anterior circulation occlusion; i.e. either the ICA or the M1/M2-segment of the MCA;\n* Stroke symptom onset has been more than 6 hours but not more than 24 hours,and imaging confirmed the existenceof ischemic penumbra;\n* NIHSS score≥6;\n* Alberta Stroke Program Early CT score (ASPECTS) of 6-10 on non- contrast CT;\n* (Level of consciousness) NIHSS score of 0 or 1\n* mRS score was 0-1 before stroke;\n* Informed consent obtained;\n\nExclusion Criteria:\n\n* Rapid improvement in neurological status to an NIHSS \\< 6 or evidence of vessel recanalization prior to randomization;\n* Seizures at stroke onset;\n* Intracranial hemorrhage;\n* Systolic pressure greater than 185 mm Hg or diastolic pressure greater than 110 mm Hg, or aggressive treatment intravenous medication)necessary to reduce blood pressure to these limits;\n* Symptoms rapidly improving;\n* Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal;\n* Platelet count of less than 100,000 per cubic millimeter;\n* CT showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere);\n* severe hepatic or renal dysfunction;\n* active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;\n* \\>3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2)#95% as per current stroke management guidelines;\n* medically unstable;\n* inability to obtain informed consent;\n* Life expectancy\\<90 days;\n* Pregnant or breast-feeding women;\n* Unwilling to be followed up or poor compliance for treatment;\n* Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial;\n* Evidence of intracranial tumor;\n* Baseline blood glucose of \\< 50 mg/dL (2.78 mmol) or \\> 400 mg/dL (22.20 mmol);\n* Patients with upper gastrointestinal bleeding or nausea and vomiting who cannot use oxygen masks;\n* Other circumstances requiring emergency oxygen inhalation;","healthyVolunteers":false,"sex":"ALL","genderBased":true,"minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xunming Ji, MD","role":"CONTACT","phone":"+86-10-83198952","email":"jixm@ccmu.edu.cn"}],"overallOfficials":[{"name":"Xunming Ji, MD","affiliation":"Xuanwu Hospital of Capital Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Xuanwu Hospital of Capital Medical University","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Weili Li, MD","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000018496","term":"Hyperoxia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000012818","term":"Signs and Symptoms, Respiratory"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M20290","name":"Hyperoxia","asFound":"Hyperoxia","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M15313","name":"Signs and Symptoms, Respiratory","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}